Over the past 12 months, 9 insiders at Crinetics Pharmaceuticals, Inc. filed 24 open-market SEC Form 4 transactions on CRNX: 0 purchases worth $0 and 24 sales worth $8.9M. Insiders have been net sellers over this period. The most recent filing was on Jul 2, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 2, 26 | Coelho Rogerio Vivaldi | SELL | 3.0K | $40.00 | $120K |
| Jun 17, 26 | Stephanie Okey | SELL | 6.3K | $36.22 | $224K |
| Apr 8, 26 | Jeff E. KnightChief Dev. & Operating Officer | SELL | 85.2K | $40.10 | $3.4M |
| Mar 16, 26 | Stephen F. BetzChief Scientific Officer | SELL | 6.4K | $37.77 | $236K |
| Mar 16, 26 | Jeff E. KnightChief Operating Officer | SELL | 6.0K | $37.77 | $221K |
| Mar 16, 26 | Richard Scott StruthersPresident & CEO | SELL | 13.2K | $37.77 | $490K |
| Mar 12, 26 | Coelho Rogerio VivaldiDirector | SELL | 4.5K | $36.77 | $162K |
| Mar 3, 26 | Stephanie OkeyDirector | SELL | 3.0K | $39.67 | $119K |
| Mar 3, 26 | Tobin SchilkeChief Financial Officer | SELL | 6.7K | $39.67 | $266K |
| Jan 5, 26 | Isabel KalofonosChief Commercial Officer | SELL | 2.5K | $55.00 | $138K |
| Dec 1, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 5.0K | $45.02 | $225K |
| Nov 3, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 4.9K | $43.27 | $209K |
| Oct 1, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 5.0K | $41.81 | $209K |
| Sep 26, 25 | Matthew K FustDirector | SELL | 16.0K | $44.75 | $716K |
| Sep 26, 25 | Richard Scott StruthersPresident & CEO | SELL | 4.0K | $45.00 | $180K |
| Sep 2, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 5.0K | $32.10 | $161K |
| Aug 22, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 30.0K | $30.43 | $913K |
| Aug 20, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 6.5K | $29.18 | $189K |
| Jun 12, 25 | Stephen F. BetzChief Scientific Officer | SELL | 97.5K | $32.23 | $3.1M |
| Mar 19, 25 | Stephen F. BetzChief Scientific Officer | SELL | 5.5K | $34.83 | $187K |
| Mar 19, 25 | Jeff E. KnightChief Operating Officer | SELL | 6.8K | $34.83 | $232K |
| Mar 19, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 2.4K | $34.83 | $82K |
| Mar 19, 25 | Richard Scott StruthersPresident & CEO | SELL | 16.5K | $34.83 | $563K |
| Feb 3, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 5.0K | $39.07 | $195K |
| Jan 3, 25 | Dana PizzutiChief Med and Dev Officer | SELL | 15.0K | $52.09 | $781K |
| Dec 2, 24 | Richard Scott StruthersPresident & CEO | SELL | 10.0K | $57.57 | $576K |
| Nov 22, 24 | Jeff E. KnightChief Operating Officer | SELL | 501 | $56.52 | $28K |
| Oct 3, 24 | Dana PizzutiChief Med and Dev Officer | SELL | 14.4K | $54.63 | $785K |
| Sep 26, 24 | Marc WilsonCFO | SELL | 25.0K | $51.11 | $1.3M |
| Sep 10, 24 | Stephen F. BetzChief Scientific Officer | SELL | 1.0K | $51.50 | $53K |
| Aug 26, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $53.19 | $160K |
| Aug 12, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $47.68 | $143K |
| Jul 25, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $53.43 | $160K |
| Jul 25, 24 | Marc WilsonCFO | SELL | 19.1K | $53.88 | $1.0M |
| Jul 15, 24 | Jeff E. KnightChief Operating Officer | SELL | 27.0K | $55.00 | $1.5M |
| Jul 15, 24 | Marc WilsonCFO | SELL | 25.0K | $55.00 | $1.4M |
| Jul 10, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $48.55 | $146K |
| Jul 5, 24 | James HassardChief Commercial Officer | SELL | 15.0K | $44.08 | $661K |
| Jul 3, 24 | Dana PizzutiChief Med and Dev Officer | SELL | 14.4K | $44.87 | $645K |
| Jun 28, 24 | Marc WilsonCFO | SELL | 32.1K | $43.61 | $1.4M |
| Jun 26, 24 | Jeff E. KnightChief Operating Officer | SELL | 956 | $44.38 | $42K |
| Jun 25, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $45.37 | $136K |
| Jun 24, 24 | Dana PizzutiChief Med and Dev Officer | SELL | 9.5K | $45.73 | $434K |
| Jun 21, 24 | James HassardChief Commercial Officer | SELL | 15.0K | $44.66 | $670K |
| Jun 10, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $43.86 | $132K |
| May 28, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $47.49 | $142K |
| May 10, 24 | Stephen F. BetzChief Scientific Officer | SELL | 3.0K | $49.43 | $148K |
| May 8, 24 | Richard Scott StruthersPresident & CEO | SELL | 107.4K | $49.40 | $5.3M |
| Apr 15, 24 | Dana PizzutiChief Med and Dev Officer | SELL | 14.4K | $44.47 | $639K |
| Apr 4, 24 | Richard Scott StruthersPresident & CEO | SELL | 41.0K | $49.17 | $2.0M |
Over the past 12 months, insiders at Crinetics Pharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 24 sales worth $8.9M on CRNX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 2, 26.
9 different insiders at Crinetics Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on CRNX over the last 12 months.
InsiderTape plots every CRNX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Crinetics Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →